BIO vs TFX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 21, 2026

BIO

63.5
AI Score
VS
BIO Wins

TFX

58.4
AI Score

Investment Advisor Scores

BIO

64score
Recommendation
BUY

TFX

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BIO TFX Winner
Revenue 1.24B 1.12B BIO
Net Income -155.70M 91.54M TFX
Gross Margin 52.7% 57.1% TFX
Net Margin -12.5% 8.2% TFX
Operating Income 106.70M 93.01M BIO
ROE -2.2% 3.2% TFX
ROA -1.5% 1.3% TFX
Total Assets 10.25B 6.79B BIO
Cash 517.00M 300.16M BIO
Debt/Equity 0.17 0.97 BIO
Current Ratio 3.14 2.60 BIO

Relative Price Performance (Last 90 Days)

BIO 1M: -5.0% · 3M: +13.9% TFX 1M: +4.4% · 3M: -0.6%

Current Technical Phase

BIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.8 · Price: $360.50

TFX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 57

RSI (14): 56.6 · Price: $130.40

Fundamentals Snapshot

Metric BIO TFX
Market Cap — —
Forward P/E 37.0 11.9
Trailing P/E 44.9 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.3%
Gross Margin 0.5% 0.6%
Operating Margin 0.1% 0.1%
EPS 7.89 -8.48
Dividend Yield — 0.01%

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.